Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

Rhea-AI Summary

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will report its third quarter 2021 financial results on November 10, 2021, before the U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company develops therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Interested parties can pre-register for the call via the provided link, and a replay will be available until November 24, 2021.

Positive

• Xeris has two commercially available products: Gvoke® and Keveyis®.
• The company has a robust pipeline for new indications and products using proprietary technology.

Negative

• None.

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 10, 2021. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.

To pre-register for the conference call please use this link: https://www.incommglobalevents.com/registration/q4inc/9056/xeris-biopharma-third-quarter-2021-financial-results/

After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, November 24, 2021, at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 508975

About Xeris Biopharma Holdings, Inc.

Xeris (Nasdaq: XERS), is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has two commercially available products, Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005312/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

312-736-1237

Source: Xeris Biopharma Holdings, Inc.

FAQ

When will Xeris Biopharma announce its third quarter 2021 financial results?

Xeris Biopharma will announce its third quarter 2021 financial results on November 10, 2021.

What time is the conference call for Xeris Biopharma's financial results?

The conference call will take place at 8:30 a.m. Eastern Time on November 10, 2021.

How can I listen to Xeris Biopharma's financial results conference call?

You can pre-register for the conference call using the link provided in the press release.

What products does Xeris Biopharma currently offer?

Xeris Biopharma currently offers Gvoke®, a liquid glucagon, and Keveyis®, the only FDA-approved therapy for primary periodic paralysis.

What is the significance of Xeris Biopharma's product pipeline?

Xeris Biopharma's product pipeline seeks to extend current marketed products into new indications and develop new products.